Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11891662 | 0.83 | LMNA (0.48) | LMNAALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL11891663 | 0.83 | LMNA (0.48) | LMNAALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL1054878 | 0.83 | LMNA (0.48) | LMNAALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL1053390 | 0.83 | HPGD (0.50) | LMNAALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL14903184 | 0.83 | BRD4 (0.43) | LMNAALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL13417273 | 0.82 | LMNA (0.55) | LMNAALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL13417154 | 0.81 | LMNA (0.52) | LMNAALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL3376310 | 0.79 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDTP53HSD17B10 | |
| SCHEMBL16495409 | 0.79 | PKN2 (0.44) | LMNAALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL3372555 | 0.79 | LMNA (0.53) | LMNAALDH1A1KDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| EP-2451780-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | AstraZeneca AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| WO-2011004182-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004182-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | CYP3A4, CYP4A11, CYP4B1 | LMNA 4139/4885ALDH1A1 539/4885KDM4E 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.